James C Barton

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8558584/publications.pdf

Version: 2024-02-01

262	7,091	76031	87275
papers	citations	42 h-index	74 g-index

267	267	267	4253
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Hydroxychloroquine Therapy and Serum Immunoglobulin Levels in Women with IgG Subclass Deficiency and Systemic Lupus Erythematosus, SjÃ¶gren Syndrome, and Rheumatoid Arthritis: A Retrospective Study. Archivum Immunologiae Et Therapiae Experimentalis, 2022, 70, 14.	1.0	1
2	Polycythemia Rubra Vera and Sporadic Bilateral Renal Angiomyolipomas: A Case Report. Cureus, 2022, 14, e24030.	0.2	0
3	Estimates of West African Ancestry in African Americans Using Alleles of Iron-Related Genes HJV, SLC40A1, and TFR2. Genetic Testing and Molecular Biomarkers, 2022, 26, 96-102.	0.3	0
4	HLA-A*03, the hemochromatosis ancestral haplotype, and phenotypes of referred hemochromatosis probands with HFE p.C282Y homozygosity. Hereditas, 2022, 159, .	0.5	3
5	Factors associated with IgG levels in adults with IgG subclass deficiency. BMC Immunology, 2021, 22, 53.	0.9	3
6	Abdominal pain and cirrhosis at diagnosis of hemochromatosis: Analysis of 219 referred probands with HFE p.C282Y homozygosity and a literature review. PLoS ONE, 2021, 16, e0261690.	1.1	0
7	Characterization of adult patients with IgG subclass deficiency and subnormal IgG2. PLoS ONE, 2020, 15, e0240522.	1.1	10
8	Increased frequency of GNPAT p.D519G in compound HFE p.C282Y/p.H63D heterozygotes with elevated serum ferritin levels. Blood Cells, Molecules, and Diseases, 2020, 85, 102463.	0.6	2
9	Estimates of European American Ancestry in African Americans Using HFE p.C282Y. Genetic Testing and Molecular Biomarkers, 2020, 24, 578-583.	0.3	3
10	Chromosome 6p SNP microhaplotypes and IgG3 levels in hemochromatosis probands with HFE p.C282Y homozygosity. Blood Cells, Molecules, and Diseases, 2020, 85, 102461.	0.6	2
11	African-centric TP53 variant increases iron accumulation and bacterial pathogenesis but improves response to malaria toxin. Nature Communications, 2020, 11, 473.	5.8	33
12	Prevalence of iron deficiency in 62,685 women of seven race/ethnicity groups: The HEIRS Study. PLoS ONE, 2020, 15, e0232125.	1.1	24
13	HLA-A and -B Type and Haplotype Frequencies in IgG Subclass Deficiency Subgroups. Archivum Immunologiae Et Therapiae Experimentalis, 2020, 68, 14.	1.0	1
14	Iron overload and cirrhosis in referred HFE p.C282Y homozygotes with normal transferrin saturation and elevated serum ferritin. Canadian Liver Journal, 2020, 3, 188-193.	0.3	1
15	Iron overload and cirrhosis in referred HFE p.C282Y homozygotes with normal transferrin saturation and elevated serum ferritin. Canadian Liver Journal, 2020, 3, 188-193.	0.3	0
16	Pneumococcal vaccination responses in adults with subnormal IgG subclass concentrations. BMC Immunology, 2019, 20, 29.	0.9	8
17	Prevalence and characteristics of anti-HCV positivity and chronic hepatitis C virus infection in HFE p.C282Y homozygotes. Annals of Hepatology, 2019, 18, 354-359.	0.6	3
18	Duration of frequent or severe respiratory tract infection in adults before diagnosis of IgG subclass deficiency. PLoS ONE, 2019, 14, e0216940.	1.1	10

#	Article	IF	Citations
19	Clinical and laboratory associations of mannose-binding lectin in 219 adults with IgG subclass deficiency. BMC Immunology, 2019, 20, 15.	0.9	5
20	Pagophagia in men with iron-deficiency anemia. Blood Cells, Molecules, and Diseases, 2019, 77, 72-75.	0.6	6
21	Hepcidin, iron, and bacterial infection. Vitamins and Hormones, 2019, 110, 223-242.	0.7	31
22	Increased Allele Frequency of GNPAT p.D519G in Compound HFE p.C282Y/p.H63D Heterozygotes with Elevated Serum Ferritin Levels. Blood, 2019, 134, 4807-4807.	0.6	0
23	Implanted ports in adults with primary immunodeficiency. Journal of Vascular Access, 2018, 19, 375-377.	0.5	1
24	Cirrhosis in Hemochromatosis: Independent Risk Factors in 368 HFE p.C282Y Homozygotes. Annals of Hepatology, 2018, 17, 871-879.	0.6	25
25	Listeria monocytogenes Infection in Hairy Cell Leukemia: A Case Report and Literature Review. Case Reports in Hematology, 2018, 2018, 1-5.	0.3	2
26	GNPAT p.D519G is independently associated with markedly increased iron stores in HFE p.C282Y homozygotes. Blood Cells, Molecules, and Diseases, 2017, 63, 15-20.	0.6	13
27	Intravenous Bevacizumab Therapy in a Patient with Hereditary Hemorrhagic Telangiectasia, ENG E137K, Alcoholic Cirrhosis, and Portal Hypertension. Case Reports in Gastroenterology, 2017, 11, 293-304.	0.3	2
28	Hypogammaglobulinemia E in 216 adults with IgG subclass deficiency and respiratory tract infections. Annals of Allergy, Asthma and Immunology, 2017, 119, 292-294.	0.5	4
29	White blood cells and subtypes in HFE p.C282Y and wild-type homozygotes in the Hemochromatosis and Iron Overload Screening Study. Blood Cells, Molecules, and Diseases, 2017, 63, 9-14.	0.6	2
30	Should we treat individuals homozygous for HFE p.Cys282Tyr with ferritin 300â€“1000 Î¼g/L?. Lancet Haematology,the, 2017, 4, e569-e570.	2.2	2
31	Diabetes inHFEHemochromatosis. Journal of Diabetes Research, 2017, 2017, 1-16.	1.0	42
32	Clinical and Laboratory Associations with Persistent Hyperferritinemia in 373 Black Hemochromatosis and Iron Overload Screening Study Participants. Annals of Hepatology, 2017, 16, 802-811.	0.6	4
33	Fibromyalgia in 300 adult index patients with primary immunodeficiency. Clinical and Experimental Rheumatology, 2017, 35 Suppl 105, 68-73.	0.4	3
34	Porphyria cutanea tarda associated withHFEC282Y homozygosity, iron overload, and use of a contraceptive vaginal ring. Journal of Community Hospital Internal Medicine Perspectives, 2016, 6, 30380.	0.4	3
35	Selective Subnormal IgG1 in 54 Adult Index Patients with Frequent or Severe Bacterial Respiratory Tract Infections. Journal of Immunology Research, 2016, 2016, 1-10.	0.9	14
36	Pica for Uncooked Basmati Rice in Two Women with Iron Deficiency and a Review of Ryzophagia. Case Reports in Medicine, 2016, 2016, 1-5.	0.3	4

#	Article	IF	Citations
37	Undiagnosed diabetes and impaired fasting glucose in HFE C282Y homozygotes and HFE wild-type controls in the HEIRS Study. BMJ Open Diabetes Research and Care, 2016, 4, e000278.	1.2	2
38	Reply. Hepatology, 2016, 63, 2056-2057.	3.6	1
39	Risk Factors for Insulin Resistance, Metabolic Syndrome, and Diabetes in 248HFEC282Y Homozygotes Identified by Population Screening in the HEIRS Study. Metabolic Syndrome and Related Disorders, 2016, 14, 94-101.	0.5	9
40	Selective subnormal IgG3 in 121 adult index patients with frequent or severe bacterial respiratory tract infections. Cellular Immunology, 2016, 299, 50-57.	1.4	24
41	Autoimmune Conditions in 235 Hemochromatosis Probands withHFEC282Y Homozygosity and Their First-Degree Relatives. Journal of Immunology Research, 2015, 2015, 1-11.	0.9	10
42	Exome sequencing in HFE C282Y homozygous men with extreme phenotypes identifies a GNPAT variant associated with severe iron overload. Hepatology, 2015, 62, 429-439.	3.6	75
43	Serum Ferritin, Insulin Resistance, and Metabolic Syndrome: Clinical and Laboratory Associations in 769 Non-Hispanic Whites Without Diabetes Mellitus in the HEIRS Study. Metabolic Syndrome and Related Disorders, 2015, 13, 57-63.	0.5	12
44	Hepatic Iron in African Americans Who Underwent Liver Biopsy. American Journal of the Medical Sciences, 2015, 349, 50-55.	0.4	4
45	HFE gene: Structure, function, mutations, and associated iron abnormalities. Gene, 2015, 574, 179-192.	1.0	97
46	Serum ferritin is a biomarker for liver mortality in the Hemochromatosis and Iron Overload Screening Study. Annals of Hepatology, 2015, 14, 348-53.	0.6	4
47	Implanted Central Venous Access Ports for Therapeutic Phlebotomy in Patients with HFE Hemochromatosis and other Non-thalassemia Iron Overload Disorders. Journal of Vascular Access, 2014, 15, 67-67.	0.5	0
48	Serum immunoglobulins in 28 adults with autoimmune sensorineural hearing loss: increased prevalence of subnormal immunoglobulin G1 and immunoglobulin G3. BMC Immunology, 2014, 15, 43.	0.9	8
49	Comparisons of CVID and IgGSD: Referring Physicians, Autoimmune Conditions, Pneumovax Reactivity, Immunoglobulin Levels, Blood Lymphocyte Subsets, and HLA-A and -B Typing in 432 Adult Index Patients. Journal of Immunology Research, 2014, 2014, 1-10.	0.9	22
50	Diabetes in First-Degree Family Members: A Predictor of Type 2 Diabetes in 159 Nonscreening Alabama Hemochromatosis Probands WithHFEC282Y Homozygosity. Diabetes Care, 2014, 37, 259-266.	4.3	9
51	Hemochromatosis and Iron Overload: From Bench to Clinic. American Journal of the Medical Sciences, 2013, 346, 403-412.	0.4	19
52	HFEMutations in Caucasian Participants of the Hemochromatosis and Iron Overload Screening Study with Serum Ferritin Level <1000 ï¼g/L. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, 390-392.	1.8	21
53	Effects of Highly Conserved Major Histocompatibility Complex (MHC) Extended Haplotypes on Iron and Low CD8+ T Lymphocyte Phenotypes in HFE C282Y Homozygous Hemochromatosis Patients from Three Geographically Distant Areas. PLoS ONE, 2013, 8, e79990.	1.1	15
54	Mild Iron Overload in an African American Man with SLC40A1 D270V. Acta Haematologica, 2012, 128, 28-32.	0.7	10

#	Article	IF	Citations
55	Predictors of Shingles Reports at Diagnosis of Common Variable Immunodeficiency and Selective Immunoglobulin G Subclass Deficiency in 212 Alabama Adults. Gastroenterology Insights, 2012, 4, e34.	0.7	3
56	Dupuytren's Contracture in Alabama HFE Hemochromatosis Probands. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, 2012, 5, CMAMD.S9935.	0.3	1
57	Recurrent Acute Kidney Injury Associated With Metastatic Bronchial Carcinoid. American Journal of the Medical Sciences, 2012, 343, 106-108.	0.4	4
58	Increased Risk of Death From Iron Overload Among 422 Treated Probands With HFE Hemochromatosis and Serum Levels of Ferritin Greater Than 1000 Î¼g/L at Diagnosis. Clinical Gastroenterology and Hepatology, 2012, 10, 412-416.	2.4	43
59	Common TMPRSS6 mutations and iron, erythrocyte, and pica phenotypes in 48 women with iron deficiency or depletion. Blood Cells, Molecules, and Diseases, 2012, 48, 124-127.	0.6	12
60	Dietary Iron Intake and Serum Ferritin Concentration in 213 Patients Homozygous for theHFE^{C282Y}Hemochromatosis Mutation. Canadian Journal of Gastroenterology & Hepatology, 2012, 26, 345-349.	1.8	22
61	A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation. Journal of Hepatology, 2011, 55, 453-458.	1.8	85
62	Sideroblastic anemia, iron overload, andALAS2R452S in African-American males: Phenotype and genotype features of five unrelated patients. American Journal of Hematology, 2011, 86, 787-789.	2.0	3
63	Hemochromatosis, <i>HFE</i> C282Y Homozygosity, and Polycystic Ovary Syndrome: Report of Two Cases and Possible Effects of Androgens and Hepcidin. Acta Haematologica, 2011, 126, 138-140.	0.7	4
64	How I treat hemochromatosis. Blood, 2010, 116, 317-325.	0.6	152
65	Longer survival associated with HLAâ€A*03, B*14 among 212 hemochromatosis probands with HFE C282Y homozygosity and HLAâ€A and â€B typing and haplotyping¹. European Journal of Haematology, 2010, 85, 439-447.	1.1	7
66	Heritability of serum iron measures in the hemochromatosis and iron overload screening (HEIRS) family study. American Journal of Hematology, 2010, 85, 101-105.	2.0	14
67	Pica associated with iron deficiency or depletion: clinical and laboratory correlates in 262 non-pregnant adult outpatients. BMC Hematology, 2010, 10, 9.	2.6	31
68	Iron toxicity. , 2010, , 28-33.		2
69	Iron overload due to excessive supplementation. , 2010, , 313-318.		0
70	Management of iron overload. , 2010, , 321-341.		3
71	HFE hemochromatosisâ€"screening, diagnosis and management. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 482-484.	8.2	5
72	Tumor necrosis factor-alpha promoter variants and iron phenotypes in 785 Hemochromatosis and Iron Overload Screening (HEIRS) Study participants. Blood Cells, Molecules, and Diseases, 2010, 44, 252-256.	0.6	7

#	Article	IF	Citations
73	Screening for Iron Overload: Lessons from the HEmochromatosis and IRon Overload Screening (HEIRS) Study. Canadian Journal of Gastroenterology & Hepatology, 2009, 23, 769-772.	1.8	37
74	Potential Nonresponse Bias in a Clinical Examination After Initial Screening Using Iron Phenotyping and HFE Genotyping in the Hemochromatosis and Iron Overload Screening Study. Genetic Testing and Molecular Biomarkers, 2009, 13, 721-728.	0.3	1
75	Bilateral Subdural Hematomas in an Adult With Hereditary Factor VII Deficiency: A Complication of Sit-ups and Inversion?. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 242-244.	0.7	2
76	HFE C282Y Homozygosity Is Associated With Lower Total and Low-Density Lipoprotein Cholesterol. Circulation: Cardiovascular Genetics, 2009, 2, 34-37.	5.1	29
77	HFE, SLC40A1, HAMP, HJV, TFR2, and FTL mutations detected by denaturing highâ€performance liquid chromatography after iron phenotyping and HFE C282Y and H63D genotyping in 785 HEIRS Study participants. American Journal of Hematology, 2009, 84, 710-714.	2.0	39
78	Hypogonadotrophic hypogonadism due to intrasellar hemangioblastoma in von Hippelâ€“Lindau syndrome. American Journal of Medical Genetics, Part A, 2009, 149A, 549-551.	0.7	1
79	A Comparison Between Whites and Blacks With Severe Multi-Organ Iron Overload Identified in 16,152 Autopsies. Clinical Gastroenterology and Hepatology, 2009, 7, 781-785.e2.	2.4	6
80	Hemochromatosis and Vibrio vulnificus Wound Infections. Journal of Clinical Gastroenterology, 2009, 43, 890-893.	1.1	59
81	Differences in Hepatic Phenotype Between Hemochromatosis Patients With HFE C282Y Homozygosity and Other HFE Genotypes. Journal of Clinical Gastroenterology, 2009, 43, 569-573.	1.1	51
82	HFE Hemochromatosis and Hepatic Sarcoid. American Journal of the Medical Sciences, 2009, 337, 386-390.	0.4	10
83	Characteristics of participants with selfâ€reported hemochromatosis or iron overload at HEIRS study initial screening. American Journal of Hematology, 2008, 83, 126-132.	2.0	12
84	Serum ferritin concentrations and body iron stores in a multicenter, multiethnic primaryâ€care population. American Journal of Hematology, 2008, 83, 618-626.	2.0	37
85	Accuracy of Family History of Hemochromatosis or Iron Overload: The Hemochromatosis and Iron Overload Screening Study. Clinical Gastroenterology and Hepatology, 2008, 6, 934-938.	2.4	16
86	Multi-Organ Iron Overload in an African-American Man with ALAS2 R452S and SLC40A1 R561G. Acta Haematologica, 2008, 120, 168-173.	0.7	19
87	Thyroid-Stimulating Hormone and Free Thyroxine Levels in Persons with HFE C282Y Homozygosity, a Common Hemochromatosis Genotype: The HEIRS Study. Thyroid, 2008, 18, 831-838.	2.4	16
88	Ferritin >1000: grand for hemochromatosis screening?. Blood, 2008, 111, 3309-3309.	0.6	63
89	Clinical Manifestations of Hemochromatosis inHFEC282Y Homozygotes Identified by Screening. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 923-930.	1.8	56
90	Psychosocial Impact of Genetic Testing for Hemochromatosis in The HEIRS Study: A Comparison of Participants Recruited in Canada And in The United States. Genetic Testing and Molecular Biomarkers, 2007, 11, 55-64.	1.7	15

#	Article	IF	Citations
91	<i>SLC40A1</i> c.1402Gâ†'A Results in Aberrant Splicing, Ferroportin Truncation after Glycine 330, and an Autosomal Dominant Hemochromatosis Phenotype. Acta Haematologica, 2007, 118, 237-241.	0.7	17
92	HFE C282Y Homozygotes Aged 25â€"29 Years at HEIRS Study Initial Screening. Genetic Testing and Molecular Biomarkers, 2007, 11, 269-275.	1.7	8
93	Serum Ferritin and Transferrin Saturation in Asians and Pacific Islanders. Archives of Internal Medicine, 2007, 167, 722.	4.3	51
94	African Americans at Risk for Increased Iron Stores or Liver Disease. American Journal of Medicine, 2007, 120, 734.e1-734.e9.	0.6	8
95	Biological Variability of Transferrin Saturation and Unsaturated Iron-Binding Capacity. American Journal of Medicine, 2007, 120, 999.e1-999.e7.	0.6	75
96	Association of ferroportin Q248H polymorphism with elevated levels of serum ferritin in African Americans in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Blood Cells, Molecules, and Diseases, 2007, 38, 247-252.	0.6	44
97	SLC40A1 Q248H allele frequencies and Q248H-associated risk of non-HFE iron overload in persons of sub-Saharan African descent. Blood Cells, Molecules, and Diseases, 2007, 39, 206-211.	0.6	31
98	Haemochromatosis. Lancet, The, 2007, 370, 1855-1860.	6.3	178
99	Optimal Management Strategies for Chronic Iron Overload. Drugs, 2007, 67, 685-700.	4.9	24
100	Determinants and characteristics of mean corpuscular volume and hemoglobin concentration in whiteHFE C282Y homozygotes in the hemochromatosis and iron overload screening study. American Journal of Hematology, 2007, 82, 898-905.	2.0	36
101	Remission of Porphyria Cutanea Tarda After Anastrozole Treatment of Breast Cancer. Clinical Breast Cancer, 2007, 7, 716-718.	1.1	4
102	Chelation therapy for iron overload. Current Gastroenterology Reports, 2007, 9, 74-82.	1.1	41
103	Genetic screening for iron overload: No evidence of discrimination at 1 year. Journal of Family Practice, 2007, 56, 829-34.	0.2	27
104	Liver Diseases in the Hemochromatosis and Iron Overload Screening Study. Clinical Gastroenterology and Hepatology, 2006, 4, 918-923.e1.	2.4	52
105	Three kinships with ALAS2 P520L (c. 1559 CÂâ†'ÂT) mutation, two in association with severe iron overload, and one with sideroblastic anemia and severe iron overload. Blood Cells, Molecules, and Diseases, 2006, 36, 292-297.	0.6	12
106	Disparate phenotypic expression of ALAS2 R452H (nt 1407 GÂâ†'ÂA) in two brothers, one with severe sideroblastic anemia and iron overload, hepatic cirrhosis, and hepatocellular carcinoma. Blood Cells, Molecules, and Diseases, 2006, 36, 342-346.	0.6	14
107	Vibrio vulnificus Bacteremia Associated with Chronic Lymphocytic Leukemia, Hypogammaglobulinemia, and Hepatic Cirrhosis: Relation to Host and Exposure Factors in 252 V. Vulnificus Infections Reported in Louisiana. American Journal of the Medical Sciences, 2006, 332, 216-220.	0.4	9
108	Effect of Native American ancestry on iron-related phenotypes of Alabama hemochromatosis probands with HFEC282Y homozygosity. BMC Medical Genetics, 2006, 7, 22.	2.1	2

#	Article	IF	Citations
109	Iron overload and prolonged ingestion of iron supplements: Clinical features and mutation analysis of hemochromatosis-associated genes in four cases. American Journal of Hematology, 2006, 81, 760-767.	2.0	33
110	Hemochromatosis and Severe Iron Overload Associated with Compound Heterozygosity for TFR2 R455Q and Two Novel Mutations TFR2 R396X and G792R. Acta Haematologica, 2006, 115, 102-105.	0.7	25
111	Relationships of Serum Ferritin, Transferrin Saturation, and HFE Mutations and Self-Reported Diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Diabetes Care, 2006, 29, 2084-2089.	4.3	85
112	Symptoms and Signs of Hemochromatosis in HFE C282Y Homozygotes Identified by Screening in Primary Care.. Blood, 2006, 108, 1545-1545.	0.6	3
113	Geographic and racial/ethnic differences in HFE mutation frequencies in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Ethnicity and Disease, 2006, 16, 815-21.	1.0	27
114	Concerns in a primary care population about genetic discrimination by insurers. Genetics in Medicine, 2005, 7, 311-316.	1.1	94
115	Management of hemochromatosis in a Jehovah's Witness. American Journal of Hematology, 2005, 78, 83-83.	2.0	5
116	Total blood lymphocyte counts in hemochromatosis probands with HFEC282Y homozygosity: relationship to severity of iron overload and HLA-A and -B alleles and haplotypes. BMC Hematology, 2005, 5, 5.	2.6	17
117	Stainable hepatic iron in 341 African American adults at coroner/medical examiner autopsy. BMC Clinical Pathology, 2005, 5, 2.	1.8	11
118	Comparison of the Unsaturated Iron-Binding Capacity with Transferrin Saturation as a Screening Test to Detect C282Y Homozygotes for Hemochromatosis in 101 168 Participants in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Clinical Chemistry, 2005, 51, 1048-1052.	1.5	41
119	Hemochromatosis and Iron-Overload Screening in a Racially Diverse Population. New England Journal of Medicine, 2005, 352, 1769-1778.	13.9	662
120	Initial Screening Transferrin Saturation Values, Serum Ferritin Concentrations, andHFEGenotypes in Whites and Blacks in the Hemochromatosis and Iron Overload Screening Study. Genetic Testing and Molecular Biomarkers, 2005, 9, 231-241.	1.7	69
121	HLA haplotype A*03-B*07 in hemochromatosis probands with C282Y homozygosity: frequency disparity in men and women and lack of association with severity of iron overload. Blood Cells, Molecules, and Diseases, 2005, 34, 38-47.	0.6	42
122	Iron overload in an African American woman with SS hemoglobinopathy and a promoter mutation in the X-linked erythroid-specific 5-aminolevulinate synthase (ALAS2) gene. Blood Cells, Molecules, and Diseases, 2005, 34, 226-228.	0.6	20
123	Relationships of Serum Ferritin, Transferrin Saturation, and HFE Mutations and Self-Reported Diabetes Mellitus in the Hemochromatosis and Iron Overload Screening (HEIRS) Study.. Blood, 2005, 106, 3713-3713.	0.6	0
124	Three Kinships with ALAS2 P520L Mutations, Two in Association with Severe Iron Overload, and One with Sideroblastic Anemia and Severe Iron Overload.. Blood, 2005, 106, 3723-3723.	0.6	0
125	Initial Screening Transferrin Saturation Values, Serum Ferritin Concentrations, and HFE Genotypes in Native Americans and Whites in the Hemochromatosis and Iron Overload Screening (HEIRS) Study.. Blood, 2005, 106, 3712-3712.	0.6	0
126	Examination of ALAS2, ABC7, Rag1, and IL6 Genes as Candidate Modifiers of Iron Overload in HFE C282Y Homozygotes with Severe Iron Overload.. Blood, 2005, 106, 3724-3724.	0.6	0

#	Article	IF	Citations
127	Deferasirox Novartis. Current Opinion in Investigational Drugs, 2005, 6, 327-35.	2.3	7
128	Attitudes about and Psychosocial Outcomes of HFE Genotyping for Hemochromatosis. Genetic Testing and Molecular Biomarkers, 2004, 8, 90-97.	1.7	18
129	Characteristics of HFE C282Y Homozygotes Younger than Age 30 Years. Acta Haematologica, 2004, 112, 219-221.	0.7	7
130	Hemojuvelin (HJV) mutations in persons of European, African-American and Asian ancestry with adult onset haemochromatosis. British Journal of Haematology, 2004, 127, 224-229.	1.2	48
131	Ancestry reported by white adults with cutaneous melanoma and control subjects in central Alabama. BMC Cancer, 2004, 4, 47.	1.1	5
132	HFE C282Y and H63D in adults with malignancies in a community medical oncology practice. BMC Cancer, 2004, 4, 6.	1.1	20
133	Hemochromatosis,<I> HFE</I> C282Y Homozygosity, and Bariatric Surgery: Report of Three Cases. Obesity Surgery, 2004, 14, 1409-1414.	1.1	10
134	Allele frequencies of hemojuvelin gene (HJV) I222N and G320V missense mutations in white and African American subjects from the general Alabama population. BMC Medical Genetics, 2004, 5, 29.	2.1	17
135	The mitochondrial nt 16189 polymorphism and hereditary hemochromatosis. Blood Cells, Molecules, and Diseases, 2004, 33, 344-345.	0.6	12
136	Genetic abnormalities and juvenile hemochromatosis: mutations of the HJV gene encoding hemojuvelin. Blood, 2004, 103, 4669-4671.	0.6	133
137	Hemojuvelin Mutations in Whites, Blacks and Asians with Primary Iron Overload and in Control Subjects.. Blood, 2004, 104, 3198-3198.	0.6	6
138	Countries of ancestry reported by hemochromatosis probands and control subjects in central Alabama. Ethnicity and Disease, 2004, 14, 73-81.	1.0	13
139	HLA-A and -B alleles and haplotypes in 240 index patients with common variable immunodeficiency and selective IgG subclass deficiency in central Alabama. BMC Medical Genetics, 2003, 4, 3.	2.1	27
140	Common variable immunodeficiency and IgG subclass deficiency in central Alabama hemochromatosis probands homozygous for HFE C282Y. Blood Cells, Molecules, and Diseases, 2003, 31, 102-111.	0.6	16
141	Ferroportin 1 (SCL40A1) variant associated with iron overload in African-Americans. Blood Cells, Molecules, and Diseases, 2003, 31, 305-309.	0.6	118
142	Genotypic and phenotypic heterogeneity of African Americans with primary iron overload. Blood Cells, Molecules, and Diseases, 2003, 31, 310-319.	0.6	65
143	Vibrio vulnificus Infection in a Hemodialysis Patient Receiving Intravenous Iron Therapy. Clinical Infectious Diseases, 2003, 37, e63-e67.	2.9	13
144	Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis. American Journal of Gastroenterology, 2003, 98, 2072-2077.	0.2	48

#	Article	IF	Citations
145	Phlebotomy-Mobilized Iron as a Surrogate for Liver Iron Content in Hemochromatosis Patients. Hematology, 2003, 8, 429-432.	0.7	15
146	Insurance, Employment, and Psychosocial Consequences of A Diagnosis of Hereditary Hemochromatosis in Subjects Without End Organ Damage. American Journal of Gastroenterology, 2003, 98, 1175-1180.	0.2	34
147	Serum Ferritin Level Predicts Advanced Hepatic Fibrosis among U.S. Patients with Phenotypic Hemochromatosis. Annals of Internal Medicine, 2003, 138, 627.	2.0	167
148	Hemochromatosis and Iron Overload Screening (HEIRS) Study Design for an Evaluation of 100,000 Primary Care-Based Adults. American Journal of the Medical Sciences, 2003, 325, 53-62.	0.4	118
149	Hemochromatosis Detection in a Health Screening Program at an Alabama Forest Products Mill. Journal of Occupational and Environmental Medicine, 2002, 44, 745-751.	0.9	15
150	Survey of physician knowledge about hemochromatosis. Genetics in Medicine, 2002, 4, 136-141.	1.1	11
151	Juvenile Hemochromatosis in the Southeastern United States: A Report of Seven Cases in Two Kinships. Blood Cells, Molecules, and Diseases, 2002, 29, 104-115.	0.6	18
152	HLA-A and -B alleles and haplotypes in hemochromatosis probands with HFEC282Y homozygosity in central Alabama. BMC Medical Genetics, 2002, 3, 9.	2.1	31
153	Transferrin Receptor-2 (TFR2) Mutation Y250X in Alabama Caucasian and African American Subjects with and without Primary Iron Overload. Blood Cells, Molecules, and Diseases, 2001, 27, 279-284.	0.6	32
154	Hemochromatosis and iron therapy of Restless Legs Syndrome. Sleep Medicine, 2001, 2, 249-251.	0.8	34
155	Inheritance of two HFE mutations in African Americans: Cases with hemochromatosis phenotypes and estimates of hemochromatosis phenotype frequency. Genetics in Medicine, 2001, 3, 294-300.	1.1	34
156	Severity of iron overload in hemochromatosis: effect of volunteer blood donation before diagnosis. Transfusion, 2001, 41, 123-129.	0.8	29
157	Organ retention and excretion of radiolead administered intravenously in rats: A Comparison of erythrocyte- and plasma-associated lead. Journal of Trace Elements in Experimental Medicine, 2001, 14, 89-98.	0.8	0
158	HFEGenotype Frequencies in Consecutive Reference Laboratory Specimens: Comparisons among Referral Sources and Association with Initial Diagnosis. Genetic Testing and Molecular Biomarkers, 2001, 5, 299-306.	1.7	8
159	Abnormalities of flavin monooxygenase as an etiology for sideroblastic anemia. American Journal of Hematology, 2000, 65, 149-153.	2.0	13
160	Iron deficiency due to excessive therapeutic phlebotomy in hemochromatosis. American Journal of Hematology, 2000, 65, 223-226.	2.0	27
161	Peripheral blood erythrocyte parameters in hemochromatosis: Evidence for increased erythrocyte hemoglobin content. Translational Research, 2000, 135, 96-104.	2.4	81
162	Population screening for hemochromatosis: Has the time finally come?. Current Gastroenterology Reports, 2000, 2, 18-26.	1.1	17

#	Article	IF	Citations
163	T-lymphocyte expression and function in hemochromatosis. , 2000, , 396-408.		7
164	Mechanisms of iron toxicity. , 2000, , 229-238.		13
165	Clinical spectrum of hepatic disease in hemochromatosis. , 2000, , 250-257.		7
166	A brief history of hemochromatosis. , 2000, , 3-7.		5
167	Hemochromatosis: a genetic definition. , 2000, , 8-12.		5
168	Hemochromatosis: population genetics. , 2000, , 42-50.		17
169	Variation of hemochromatosis prevalence and genotype in national groups. , 2000, , 51-62.		17
170	Human leukocyte antigen (HLA) association and typing in hemochromatosis. , 2000, , 63-74.		9
171	The ancestral haplotype in hemochromatosis. , 2000, , 91-98.		9
172	The absorption and metabolism of non-ferrous metals in hemochromatosis. , 2000, , 131-144.		2
173	Hepatic iron metabolism in hemochromatosis. , 2000, , 157-162.		4
174	Histochemistry of iron and iron-associated proteins in hemochromatosis. , 2000, , 200-218.		2
175	Computed tomography and magnetic resonance imaging in the diagnosis of hemochromatosis. , 2000, , 219-226.		2
176	Iron as a carcinogen. , 2000, , 239-249.		8
177	The arthropathy of hemochromatosis. , 2000, , 258-267.		5
178	Non-diabetic endocrinopathy in hemochromatosis. , 2000, , 278-289.		12
179	Cutaneous manifestations of hemochromatosis. , 2000, , 290-296.		4
180	Cardiac abnormalities in hemochromatosis. , 2000, , 297-311.		13

#	Article	IF	Citations
181	Estimate of the frequency of morbid complications of hemochromatosis. , 2000, , 312-317.		1
182	Juvenile hemochromatosis. , 2000, , 318-326.		7
183	Management of hemochromatosis. , 2000, , 329-338.		1
184	Chelation therapy in iron overload. , 2000, , 339-354.		3
185	Survival in hemochromatosis. , 2000, , 359-368.		2
186	Role of iron in infections and immunity. , 2000, , 371-380.		2
187	Bacterial infections in hemochromatosis. , 2000, , 381-386.		6
188	Chronic viral hepatitis and hemochromatosis. , 2000, , 387-395.		1
189	The iron phenotype of hemochromatosis heterozygotes. , 2000, , 411-418.		7
190	Hemochromatosis, iron overload, and porphyria cutanea tarda. , 2000, , 453-467.		11
191	Iron overload in African Americans. , 2000, , 475-484.		6
192	Cost-effectiveness of screening for hemochromatosis. , 2000, , 525-532.		1
193	Hemochromatosis: effect of iron fortification of foods. , 2000, , 535-543.		4
194	Transfusion Iron Overload in Adults with Acute Leukemia: Manifestations and Therapy. American Journal of the Medical Sciences, 2000, 319, 73-78.	0.4	27
195	Transferrin Saturation Phenotype andHFEGenotype Screening for Hemochromatosis and Primary Iron Overload: Predictions from a Model Based on National, Racial, and Ethnic Group Composition in Central Alabama. Genetic Testing and Molecular Biomarkers, 2000, 4, 199-206.	1.7	14
196	Screening for Hemochromatosis in Routine Medical Care: An Evaluation of Mean Corpuscular Volume and Mean Corpuscular Hemoglobin. Genetic Testing and Molecular Biomarkers, 2000, 4, 103-110.	1.7	6
197	Transfusion Iron Overload in Adults with Acute Leukemia: Manifestations and Therapy. American Journal of the Medical Sciences, 2000, 319, 73.	0.4	35
198	Diagnosis of hemochromatosis in family members of probands: A comparison of phenotyping and HFE genotyping. Genetics in Medicine, 1999, 1, 89-93.	1.1	18

#	Article	IF	Citations
199	A survey of 2,851 patients with hemochromatosis:. American Journal of Medicine, 1999, 106, 619-624.	0.6	207
200	Two Novel Missense Mutations of the HFE Gene (I105T and G93R) and Identification of the S65C Mutation in Alabama Hemochromatosis Probands. Blood Cells, Molecules, and Diseases, 1999, 25, 147-155.	0.6	150
201	Hereditary Hemochromatosis. JAMA - Journal of the American Medical Association, 1998, 280, 172.	3.8	253
202	Management of Hemochromatosis. Annals of Internal Medicine, 1998, 129, 932.	2.0	223
203	Coinheritance of Alleles Associated With Hemochromatosis and Hereditary Hyperferritinemia-Cataract Syndrome. Blood, 1998, 92, 4480-4481.	0.6	30
204	Genetic and Clinical Description of Hemochromatosis Probands and Heterozygotes: Evidence That Multiple Genes Linked to the Major Histocompatibility Complex Are Responsible for Hemochromatosis. Blood Cells, Molecules, and Diseases, 1997, 23, 135-145.	0.6	153
205	Diagnosis of Hemochromatosis Probands in a Community Hospital. American Journal of Medicine, 1997, 103, 498-503.	0.6	36
206	Hemochromatosis: Association of Severity of Iron Overload with Genetic Markers. Blood Cells, Molecules, and Diseases, 1996, 22, 195-204.	0.6	51
207	Hemochromatosis: The genetic disorder of the twentyâ€“first century. Nature Medicine, 1996, 2, 394-395.	15.2	48
208	Iron overload in African Americans. American Journal of Medicine, 1995, 99, 616-623.	0.6	115
209	Radioimmunometric Quantification of Surface Lactoferrin in Blood Mononuclear Cells. American Journal of the Medical Sciences, 1994, 307, 102-107.	0.4	22
210	Neutrophil Function in Chronic Neutrophilic Leukemia: Defective Respiratory Burst in Response to Phorbol Esters. Acta Haematologica, 1992, 87, 16-21.	0.7	14
211	Normal Transferrin Saturation in Hemochromatosis. Hospital Practice (1995), 1991, 26, 45-48.	0.5	11
212	Immunoreactive lactoferrin in resting, activated, and neoplastic lymphocytes. Leukemia Research, 1990, 14, 441-447.	0.4	8
213	Retention of radiolead by human erythrocytes in vitro. Toxicology and Applied Pharmacology, 1989, 99, 314-322.	1.3	13
214	Tumor lysis syndrome in nonhematopoietic neoplasms. Cancer, 1989, 64, 738-740.	2.0	61
215	Prevalence of granual lymphocyte proliferation in patients with rheumatoid arthritis and neutropenia. American Journal of Medicine, 1989, 86, 303-307.	0.6	36
216	Neutrophil lactoferrin content: Variation among mammals. The Anatomical Record, 1988, 221, 567-575.	2.3	12

#	Article	IF	Citations
217	Differential staining of neutrophils and monocytes: Surface and cytoplasmic iron-binding proteins. The Histochemical Journal, 1988, 20, 147-155.	0.6	7
218	Assessment of total immunoreactive lactoferrin in hematopoietic cells using flow cytometry. Journal of Immunological Methods, 1988, 108, 159-170.	0.6	11
219	Effect of Iron Deficiency on Bleomycin-induced Lung Fibrosis in the Hamster. The American Review of Respiratory Disease, 1988, 137, 85-89.	2.9	64
220	Case Report: Neoplastic Meningitis with Eosinophilic Pleocytosis in Hodgkinâ€™s Disease: A Case with Cerebellar Dysfunction and a Review of the Literature. American Journal of the Medical Sciences, 1988, 296, 322-326.	0.4	20
221	Case Report: Immune Thrombocytopenia: Effects of Maternal Gamma Globulin Infusion on Maternal and Fetal Serum, Platelet, and Monocyte IgG. American Journal of the Medical Sciences, 1987, 293, 112-118.	0.4	8
222	Acute cryoglobulinemic renal failure after intravenous infusion of gamma globulin. American Journal of Medicine, 1987, 82, 624-629.	0.6	91
223	Rheumatoid Arthritis Associated with Expanded Populations of Granular Lymphocytes. Annals of Internal Medicine, 1986, 104, 314.	2.0	52
224	Bone Metastases in Malignant Gastrinoma. Gastroenterology, 1986, 91, 1179-1185.	0.6	40
225	Ultrastructural localization of transferrin, transferrin receptor, and ironâ€binding sites on human placental and duodenal microvilli. British Journal of Haematology, 1985, 60, 81-89.	1.2	88
226	Calcium Inhibition of Inorganic Iron Absorption in Rats. Gastroenterology, 1983, 84, 90-101.	0.6	99
227	15-hydroxyprostaglandin dehydrogenase and Î”13 reductase content of gastrointestinal organs of rabbits and rats. Prostaglandins, 1981, 21, 15-23.	1.2	17
228	Factors affecting iron balance. American Journal of Hematology, 1981, 10, 199-225.	2.0	53
229	Ultrastructural cytochemistry and radioautography of hemoglobinâ€”iron absorption. Experimental and Molecular Pathology, 1981, 34, 131-144.	0.9	57
230	Iron, Lead, and Cobalt Absorption: Similarities and Dissimilarities. Experimental Biology and Medicine, 1981, 166, 64-69.	1.1	20
231	Isolated marrow lymphoma: An entity of possible T-cell derivation. Cancer, 1980, 46, 1767-1774.	2.0	17
232	Acute lymphoblastic leukemia in idiopathic refractory sideroblastic anemia: Evidence for a common lymphoid and myeloid progenitor cell. American Journal of Hematology, 1980, 9, 109-115.	2.0	56
233	Provoked priapism in sickle cell anemia. American Journal of Hematology, 1980, 9, 121-122.	2.0	6
234	Isolated Chylopericardium Associated With Lymphoma. Southern Medical Journal, 1980, 73, 1551-1552.	0.3	12

#	Article	IF	Citations
235	Beneficial Effects of Hepatitis in Patients with Acute Myelogenous Leukemia. Annals of Internal Medicine, 1979, 90, 188.	2.0	60
236	The aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome. American Journal of Hematology, 1979, 7, 61-67.	2.0	9
237	Pseudochloroma: Extramedullar Hematopoietic Nodules in Chronic Myelogenous Leukemia. Annals of Internal Medicine, 1979, 91, 735.	2.0	20
238	Current status of blastic transformation in chronic myelogenous leukemia. American Journal of Hematology, 1978, 4, 281-291.	2.0	24
239	Effects of Ethanol on the Absorption and Retention of Lead. Experimental Biology and Medicine, 1978, 159, 213-218.	1.1	4
240	Iron overload in Native Africans and African-Americans. , 0, , 211-221.		0
241	History of iron overload disorders. , 0, , 1-9.		0
242	Tests for hemochromatosis and iron overload. , 0, , 34-64.		0
243	Complications of hemochromatosis and iron overload. , 0, , 65-107.		3
244	Infections and immunity. , 0, , 112-126.		0
245	Hemochromatosis associated with ferroportin gene (SLC40A1) mutations. , 0, , 171-180.		1
246	Hemochromatosis associated with hepcidin gene (HAMP) mutations. , 0, , 189-192.		0
247	Hemochromatosis associated with transferrin receptor-2 gene (TFR2) mutations. , 0, , 193-199.		0
248	Iron overload associated with IRE mutation of ferritin heavy-chain gene (FTH1). , 0, , 200-202.		0
249	Iron overload associated with thalassemia syndromes. , 0, , 233-241.		0
250	Iron overload associated with hemoglobinopathies. , 0, , 242-250.		0
251	Iron overload associated with pyruvate kinase deficiency. , 0, , 251-253.		0
252	Hereditary aceruloplasminemia. , 0, , 284-289.		0

#	Article	IF	Citations
253	Pantothenate kinase (PANK2)-associated neurodegeneration. , 0, , 294-298.		0
254	Neuroferritinopathies. , 0, , 299-303.		0
255	GRACILE syndrome. , 0, , 304-307.		0
256	Neonatal hemochromatosis. , 0, , 308-312.		0
257	Localized iron overload. , 0, , 319-320.		0
258	Hereditary hyperferritinemia-cataract syndrome: IRE mutations of ferritin light-chain gene (FTL). , 0, , 203-210.		0
259	Iron overload associated with congenital dyserythropoietic anemias. , 0, , 254-259.		0
260	Hereditary atransferrinemia. , 0, , 222-227.		0
261	Heterozygosity for HFE C282Y. , 0, , 149-159.		0
262	Classical and atypical HFE hemochromatosis. , 0, , 127-148.		0